Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map.
Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments.
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p1692 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/1692 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115130931&doi=10.1080%2f02770903.2021.1978483&partnerID=40&md5=7cfae083e0cc9408f6e634fe85ea7b27 |
| Access Level: | acceso abierto |
| Palabra clave: | Benralizumab, Dupilumab: Omalizumab, Mepolizumab, Reslizumab, Severe asthma, monoclonal antibodies |
| Sumario: | Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. |
|---|